PTC Therapeutics exec sells shares, exercises options
PTC Therapeutics executive Mark Elliott Boulding reported both sales and option exercises in PTC THERAPEUTICS, INC. common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
PTC Therapeutics executive Mark Elliott Boulding reported both sales and option exercises in PTC THERAPEUTICS, INC. common stock. On July 6, 2026, he sold 5,079 shares in a series of open‑market transactions at weighted average prices spanning $82.76 to $86.73. These sales were executed under a written Rule 10b5‑1 trading plan adopted on September 10, 2025.
On the same date, he exercised stock options to acquire 5,039 shares at strike prices of $46.54 and $39.42. Following the transactions, Boulding directly owns 105,272 shares of PTC Therapeutics common stock, and the filing shows remaining stock options outstanding in multiple series.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
12 txns
Insider
Boulding Mark Elliott
Role
EXEC. VP AND CLO
Sold
5,079 shs ($432K)
Approx. gross sale proceeds
$432K
Approx. exercise cost
$219K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 2,226 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 2,813 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,266 | $39.42 | $89K |
| Sale | Common Stock | 313 | $83.10 | $26K |
| Sale | Common Stock | 833 | $84.41 | $70K |
| Sale | Common Stock | 519 | $85.84 | $45K |
| Sale | Common Stock | 601 | $86.38 | $52K |
| Exercise | Common Stock | 2,813 | $46.54 | $131K |
| Sale | Common Stock | 387 | $83.10 | $32K |
| Sale | Common Stock | 1,036 | $84.41 | $87K |
| Sale | Common Stock | 645 | $85.84 | $55K |
| Sale | Common Stock | 745 | $86.38 | $64K |
Holdings After Transaction:
Stock Option (Right to Buy) — 32,657 contracts (Direct);
Common Stock — 105,272 shares (Direct)
Footnotes (7)
- F1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.
- F2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $82.76 to $83.68 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F3. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $83.98 to $84.94 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F4. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.18 to $86.17 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F5. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $86.18 to $86.73 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F6. This option was granted on January 5, 2023 and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.
- F7. This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026.
Key Figures
Shares sold: 5,079 shares
Shares acquired via option exercise: 5,039 shares
Post-transaction common shares held: 105,272 shares
+5 more
8 metrics
Shares sold
5,079 shares
Common Stock open-market sales on July 6, 2026
Shares acquired via option exercise
5,039 shares
Common Stock from option exercises on July 6, 2026
Post-transaction common shares held
105,272 shares
Direct ownership after July 6, 2026 transactions
Sale price range
$82.76–$86.73 per share
Weighted average sale price bands for multiple trades
Option strike price 1
$46.54 per share
Stock option (Right to Buy) exercised into 2,813 shares
Option strike price 2
$39.42 per share
Stock option (Right to Buy) exercised into 2,266 shares
Remaining options at $46.54
28,125 options
Stock options outstanding, expiring January 2, 2035
Remaining options at $39.42
4,532 options
Stock options outstanding, expiring January 4, 2033
Key Terms
Rule 10b5-1 plan, weighted average price, Stock Option (Right to Buy), vests over four years, +1 more
5 terms
Rule 10b5-1 plan financial
"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average price financial
"This price represents the weighted average price of sale transactions that were executed in multiple trades"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
vests over four years financial
"This option was granted on January 5, 2023 and vests over four years"
A grant that "vests over four years" is a promise that ownership of awarded company shares or options becomes permanent in small portions over a four-year period instead of all at once. Think of it like earning a four-year subscription one month at a time: the recipient gains the right to a bit more stock as time passes, which matters to investors because it affects when employees can sell shares, how quickly ownership shifts, and the timing of potential dilution or insider selling.
derivative exercise/conversion financial
"transaction_action: derivative exercise/conversion"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did PTCT executive Mark Elliott Boulding report?
Mark Elliott Boulding reported both sales and option exercises in PTC Therapeutics common stock. He sold 5,079 shares in open‑market transactions and exercised stock options to acquire 5,039 shares, all dated July 6, 2026, according to the Form 4 data.
Were Mark Elliott Boulding’s PTCT stock sales made under a Rule 10b5-1 plan?
Yes. The Form 4 footnotes state the transactions were effected under a written Rule 10b5‑1 trading plan. This plan was adopted on September 10, 2025, indicating the July 6, 2026 sales were pre‑arranged rather than timed on a discretionary, same‑day basis.
What stock options in PTCT did Boulding exercise, and what are their strike prices?
Boulding exercised options covering 5,039 underlying PTCT shares. These options had exercise prices of $46.54 and $39.42 per share. Footnotes explain the options were originally granted in 2023 and 2025 and vest over four years in scheduled quarterly installments.
AI-generated analysis. How Rhea-AI works. Not financial advice.
